Albireo

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Sickle cell disease, University, Medicine, Doctor of Philosophy, Albireo, New Drug Application, Patient, SVP, Research, Losmapimod, Senior, Homocystinuria, Facioscapulohumeral muscular dystrophy, Therapy, DRS, Hereditary angioedema, Drug development, Interim, Boston, Fulcrum, PFIC, DSM-IV codes, Pharmaceutical industry

CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as chief medical officer, effective immediately. Dr. Horn is a seasoned executive with over 20 years of end-to-end drug development experience spanning multiple therapeutic areas, with an emphasis on rare diseases, across both large pharmaceutical and biotech companies. Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development. Together, Drs. Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.

Key Points: 
  • Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development.
  • Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.
  • His most recent role was as the Chief Medical Officer at HemoShear Therapeutics, specializing in rare metabolic diseases.
  • Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Retrieved on: 
Thursday, February 8, 2024
GLT, Growth, Certification, Prostate cancer, Palovarotene, Statute, Alagille syndrome, Primary biliary cholangitis, PDAC, Patient, FDA, FOP, Cabozantinib, Food, PBC, Botulinum toxin, Irinotecan, Ipsen, Phase, Acquisition, Environment, Albireo, Bank statement, Webcast, Carbon accounting, Core, Woman, Pharmaceutical industry

Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.

Key Points: 
  • Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.
  • Ipsen anticipates four commercial launches in 2024, following regulatory decisions for Onivyde in 1L PDAC in the U.S (H1), elafibranor in second-line PBC in the U.S. (H1) and in the E.U.
  • Ipsen has set the following financial guidance for FY 2024, which excludes any impact from potential late-stage external-innovation transactions:
    Total-sales growth greater than 6.0%, at constant currency.
  • The performance shown in this announcement covers the twelve-month period to 31 December 2023 (FY 2023) and the three-month period to 31 December 2023 (Q4 2023), compared to the twelve-month period to 31 December 2022 (FY 2022) and the three-month period to 31 December 2022 (Q4 2022), respectively, unless stated otherwise.

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

Retrieved on: 
Tuesday, December 12, 2023
Ipsen, Swedish Orphan Biovitrum, Myenteric plexus, Drug development, Albireo, Stallergenes Greer, Holding, Therapy, Suffolk University Law School, Dickinson College, Merck Serono, Patient, Acushnet Company, Management

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer.

Key Points: 
  • WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer.
  • Mr. Duncan will be a member of Neumora’s Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company’s legal and compliance functions.
  • Mr. Duncan has more than two decades of legal, compliance, development and operations experience in the life sciences industry.
  • I look forward to working with Neumora’s talented team as we seek to pioneer a new era in brain disease,” said Jason Duncan, chief legal officer, Neumora.

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Retrieved on: 
Tuesday, November 14, 2023
HM, Albireo, Therapy, Notifiable disease, Biotechnology, LSE, Arrow, Cambridge Antibody Technology, Science, CAT, London Stock Exchange, Cellular senescence, RNA, OBE, Pharmaceutical industry, Management

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Key Points: 
  • SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman
    Exeter, UK — 14 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces the appointment of Dr. David Chiswell Ph.D, OBE as Chairman of the Board.
  • Dr. Chiswell has served as the Chairman of the Board of various biotechnology companies including Albireo, Arrow and Sosei.
  • Dr. Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA.
  • I am thrilled to be joining the Company as Chairman, and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.”

Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet

Retrieved on: 
Friday, September 1, 2023
Chem, IPN, PK, Mace Head Atmospheric Research Station, Business development, PD, Biochemistry, ADR, Metabolism, CSO, EVP, GU, DUT, Research, Inflammation, ELT, Institut Pasteur Korea, Research and development, Patient, European, Machine learning, Pasteur Institute, Drug discovery, Biology, Alexion, Recep Tayyip Erdoğan university diploma controversy, Albireo, Therapy, Pfizer, Management, Pharmaceutical industry, Ipsen, Neuroscience, Euronext, Christelle

She will succeed Howard Mayer, EVP and Head of R&D, who will leave Ipsen on September 22, following his decision to retire.

Key Points: 
  • She will succeed Howard Mayer, EVP and Head of R&D, who will leave Ipsen on September 22, following his decision to retire.
  • Christelle Huguet will serve on the Executive Leadership Team (ELT), reporting directly to Ipsen’s Chief Executive Officer, David Loew and immediately succeeding Howard upon his departure.
  • “I am very pleased that Christelle will join Ipsen’s Executive Leadership team as we continue to successfully deliver on our strategic roadmap.
  • “I know firsthand that our R&D organization is committed to Ipsen’s ambitious innovation agenda,” said Christelle Huguet.

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, August 23, 2023
Psychiatry, Insurance, IDR, Medical Affairs Bureau, Ipsen, Clinical trial, GHRS, DSM-IV codes, G&A, MADRS, Bipolar II disorder, Acquisition, Patient, Master of Science, Grammatical mood, Albireo, Research, FDA, TRD, IND, Pharmaceutical industry, Cryptocurrency, MD, Sanofi

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates.

Key Points: 
  • DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates.
  • R&D expenses were $7.2 million for the quarter ended June 30, 2023, compared to $4.2 million for the same quarter in 2022.
  • G&A expenses were $2.7 million for the quarter ended June 30, 2023, compared to $2.5 million for the same quarter in 2022.
  • The net profit in the prior year quarter was due to a foreign exchange gain which was not repeated in 2023.

Albireo Energy Publishes 2022 ESG Report

Retrieved on: 
Thursday, June 29, 2023
Commercial Building & Real Estate, Construction & Property, Professional Services, Building Systems, Environmental, Social and Governance (ESG), Utilities, Green Technology, Alternative Energy, Environment, Energy, Sustainability, Workforce, Huron Capital Partners, U.N, Culture, Electricity, Global Reporting Initiative, Platinum, Multimedia, Shining Star, Sustainability accounting, Great Places, Sustainability Accounting Standards Board, Natural gas, Biophysical environment, ESG, Social, Albireo, Automation, Renewable energy, Risk management

The Albireo Energy 2022 ESG Report is available for download at www.albireoenergy.com .

Key Points: 
  • The Albireo Energy 2022 ESG Report is available for download at www.albireoenergy.com .
  • View the full release here: https://www.businesswire.com/news/home/20230629367140/en/
    The Albireo Energy 2022 ESG Report highlights the performance and management of the company's commitments to address environmental, social and governance priorities.
  • “At Albireo Energy, we work with building owners and their teams to achieve operating performance, decarbonization and sustainability goals,” said Larry G. Wash, CEO of Albireo Energy.
  • “Sustainability is critical to our company’s future and integrated into how we engage our employees, operate our business and serve our customers.”
    Highlights from the Albireo Energy 2022 ESG Report include:
    Establishing and quantifying the Albireo Energy Sustainability Solutions portfolio, recognizing that 66% of the company’s gross revenue is directly attributed to helping customers address sustainability goals.

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Retrieved on: 
Thursday, March 2, 2023
Apache iBATIS, Rare, Albireo, Biliary atresia, CVR, Alagille syndrome, Ageing, Hepatology, PSC, Patient, Ascending cholangitis, Itch, ALGS, PDUFA, PFIC, Primary sclerosing cholangitis, ADR, Liver disease, Priority review, Therapy, BA, EMA, NTCP, Acquisition, IPN, Pharmaceutical industry, Vaccine, Ipsen, Euronext, Phase, Odevixibat

The acquisition enriches Ipsen’s Rare Disease portfolio, with promising therapeutics for pediatric and adult rare cholestatic-liver diseases, innovative pipeline potential, as well as scientific and commercial capabilities.

Key Points: 
  • The acquisition enriches Ipsen’s Rare Disease portfolio, with promising therapeutics for pediatric and adult rare cholestatic-liver diseases, innovative pipeline potential, as well as scientific and commercial capabilities.
  • “The acquisition of Albireo will greatly strengthen our portfolio in rare diseases,” said David Loew, Chief Executive Officer of Ipsen.
  • “I am excited to welcome new colleagues to Ipsen, who led the innovation on the development of novel bile acid modulators, like Bylvay, to treat rare liver diseases in children and adults.
  • As part of the transaction, Ipsen has also acquired A3907 and A2342, two clinical-stage assets in Albireo’s pipeline.

ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO

Retrieved on: 
Tuesday, January 24, 2023
Class Action Lawsuit, Professional Services, Legal, KSF, Sale, Biliary atresia, Food, CVR, Albireo, Odevixibat

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Albireo Pharma, Inc. (NasdaqCM: ALBO) to Ipsen S.A.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Albireo Pharma, Inc. (NasdaqCM: ALBO) to Ipsen S.A.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm

Retrieved on: 
Wednesday, February 8, 2023
ABP, PLLC, Series, Ipsen, Albireo, Wall Street, Fraud, Therapy, Bank, Security (finance)

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
    Albireo has agreed to merge with Ipsen.
  • Under the proposed transaction, Albireo shareholders will receive $42.00 in cash plus a contingent value right of $10.00 per share.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.